Last year, President Clinton made clear the urgent need for an effective HIV vaccine, and suggested that it should be possible to create one within ten years. The authors agree. Although recent progress should not be underestimated, many obstacles remain some technical, others not. Here, Dennis Burton (Scripps Research Institute) and John Moore (Aaron Diamond AIDS Research Center) outline their views on the state of development of an HIV vaccine and the areas in which more effort should be focused.
Article PDF
References
Desrosiers, R.C. Non-human primate models for AIDS vaccines. AIDS 9 (Suppl. A), S137–S141 (1995).
Burton, D.R. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. USA 94, 10018–10023 (1997).
Trkola, A. et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-lgG. J. Virol. 69, 11, 6609–6617 (1995).
Moore, J.P. & Ho, D.D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9 (suppl A), S117–S136 (1995).
Rowland-Jones, S., Tan, R. & McMichael, A. The role of cellular immunity in protection against HIV infection. Adv. Immunol. 65, 448–455 (1997).
Jassoy, C. & Walker, B.D. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Sem. Immunopathol. 18, 341–354 (1997).
Oldstone, M.B.A. HIV versus cytotoxic T lymphocytes: the war being lost. N. Eng. J. Med. 337, 1306–1308 (1997).
Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205–211 (1997).
Rowland-Jones, S.L. & McMichael, A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr. Opin. Immunol. 7, 448–455 (1995).
Hasenkrug, K.J. & Chesebro, B. Immunity to retroviral infection: the Friend virus model. Proc. Natl. Acad. Sci. USA 94, 7811–7816 (1997).
Baldridge, J.R., McCraw, T.S., Paoletti, A. & Buchmeier, M.J. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J. Virol. 71, 755–758 (1997).
Planz, O. et al. A critical role for neutralizing-antibody-producing B cells, CD4+ T cells, and interferons in persistent and acute infections of mice with lymphocyte choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA 94, 6874–6879 (1997).
Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ T cell response associated with control of viremia. Science 278, 1447–1450 (1997).
Ezzell, C. The monkey's got AIDS: what now for live AIDS vaccines? Journal of NIH Research 9, 21–22 (1997).
Stott, E.J. & Schild, G.C. Strategies for AIDS vaccines. J. Antimicro. Chemother. 37 Suppl. B, 185–198 (1996).
Sharpe, S.A., Whatmore, A.M., Hall, G.A. & Cranage, M.P. Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-re-vertant virus. J. Gen. Virol. 78, 1923–1927 (1997).
Shibata, R., Siemon, C., Czajak, S.C., Desrosiers, R.C. & Martin, M.A. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 71, 8141–8148 (1997).
Deacon, N.J. et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988–991 (1995).
Connor, R.I. et al. Immunological and virologicat analyses of persons infected by human immunodeficieny virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552–1576 (1998).
Haynes, B.F. HIV vaccines: where we are and where we are going. Lancet 348, 933–937 (1996).
VanCott, T.C. et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomericgp120. J. Virol. 71, 4319–4330 (1997).
Excler, J.-L. & Plotkin, S. The prime-boost concept applied to HIV preventative vaccines. AIDS 11, S127–S137 (1997).
Liu, M.A. Nature Med. (1998). See this issue [Insert page #s].
Graham, B.S. et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of current AIDS vaccines. J. Infect. Dis. 177, 310–319 (1998).
Corey, L. et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J. Infect. Dis. 177, 301–309 (1998).
Bloom, B.R. The highest attainable standard: ethical issues in AIDS vaccines. Science 279, 186–188 (1998).
Nossal, G. Host immunobiology and vaccine development. The Lancet 350, 1316–1319 (1997).
Berman, P.W. et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. Infect. Dis. 176, 384–397 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Burton, D., Moore, J. Why do we not have an HIV vaccine and how can we make one?. Nat Med 4 (Suppl 5), 495–498 (1998). https://doi.org/10.1038/nm0598supp-495
Issue Date:
DOI: https://doi.org/10.1038/nm0598supp-495
This article is cited by
-
Immunogenicity of the outer domain of a HIV-1 clade C gp120
Retrovirology (2007)
-
Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni
Medical Microbiology and Immunology (2005)
-
Reductionism and complexity in molecular biology
EMBO reports (2004)
-
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
Nature Medicine (1999)
-
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
Nature Medicine (1999)